Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Molecular Mimicry in T Cell-Mediated Autoimmunity: Viral Peptides Activate Human T Cell Clones Specific for Myelin Basic Protein

Kai W. Wucherpfennig and Jack L. Strominger
Department of Molecular and Cellular Biology
Harvard University
Cambridge, Massachusetts 02138

Summary

Structural similarity between viral T cell epitopes and self-peptides could lead to the induction of an autoimmune T cell response. Based on the structural requirements for both HLA class II binding and TCR recognition of an immunodominant myelin basic protein (MBP) peptide, criteria for a data base search were developed in which the degeneracy of amino acid side chains required for HLA class II binding and the conservation of those required for T cell activation were considered. A panel of 129 peptides that matched the molecular mimicry motif was tested on seven MBP-specific T cell clones from multiple sclerosis patients. Seven viral and one bacterial peptide efficiently activated three of these clones. Only one peptide could have been identified as a molecular mimic by sequence alignment. The observation that a single T cell receptor can recognize quite distinct but structurally related peptides from multiple pathogens has important implications for understanding the pathogenesis of autoimmunity.

Introduction

Activation of autoreactive T cells is a critical event in the induction of autoimmunity. In animal models of T cell-mediated autoimmunity, disease can be transferred only with activated but not with resting T cells specific for a central nervous system (CNS)-specific autoantigen (reviewed by Zamvil and Steinman, 1990). Resting autoreactive T cells are part of the normal immune repertoire and do not induce disease as the blood–brain barrier limits access to the CNS to activated T cells (Schluesser and Wekerle, 1985; Burns et al., 1983; Ota et al., 1990; Martin et al., 1990; Pette et al., 1990). This protective mechanism makes circulating self-reactive T cells "ignorant" of the complex set of tissue-specific self-antigens hidden behind the blood–brain barrier. Invasion of the CNS requires autoreactive T cells to be activated in the peripheral immune system. This activation occurs in the absence of their nominal self-antigen, which is sequestered in the CNS (Wekerle et al., 1986; Hickey et al., 1991). Two mechanisms could account for the activation and clonal expansion of autoreactive T cells in the periphery: activation by bacterial or viral superantigens that trigger T cells bearing particular T cell receptor VB segments (Brocke et al., 1993; Cole and Griffiths, 1993; Conrad et al., 1994), or activation by viral or bacterial peptides that have sufficient sequence similarity with an immunodominant self-peptide (molecular mimicry) (Oldstone, 1990).

A large body of clinical and epidemiological evidence indicates that infections are important in the induction of autoimmunity. Particular viral infections frequently precede autoimmune myocarditis and type I diabetes (IDDM) (Rose et al., 1986; Ray et al., 1980). Also, an inflammatory CNS disease can follow infection with a number of common viral pathogens, such as measles and rubella. The absence of virus in the CNS and reactivity to myelin basic protein (MBP) in these patients suggest an autoimmune mechanism (Johnson et al., 1984). Environmental agents also influence the risk of developing multiple sclerosis (MS) as demonstrated by migration studies. Individuals who migrate after age 15 carry the risk for developing MS associated with their geographic origin, while individuals who migrate earlier in life acquire the risk of the geographical region to which they migrated (Kurtzke, 1985). These studies are consistent with the hypothesis that a group of pathogens that are relatively ubiquitous in a certain geographic region influence the risk of developing MS.

Recent immunological studies suggest that MBP may be one of the important target antigens in the immunopathogenesis of MS. Several studies have demonstrated that MBP-specific T cells are clonally expanded in MS patients and in an in vivo activated state (Allegretta et al., 1990; Wucherpfennig et al., 1994b; Zhang et al., 1994). Reactivity with the immunodominant MBP(84–102) peptide is found predominantly in subjects carrying HLA-DR2, a genetic marker for susceptibility to MS. The MBP(84–102) epitope can also be presented by other major histocompatibility complex (MHC) class II alleles, including HLA-DQ1 (Ota et al., 1990; Martin et al., 1990; Pette et al., 1990; Wucherpfennig et al., 1994a). In vivo, the T cell response to this peptide appears to be dominated by a few expanded clones. The mechanism(s) leading to clonal expansion of MBP-reactive T cells remains to be identified, but could involve recognition of viral peptides with sufficient structural similarity to the immunodominant MBP peptide. Viruses that cause latent and/or persistent infections (such as the herpes simplex and Epstein–Barr viruses) would be particularly interesting candidates, as they may permit chronic antigenic stimulation of these autoreactive T cell clones. The initiation of autoimmunity by such a mechanism could then lead to sensitization to other CNS self-antigens by determinant spreading (Lehmann et al., 1992; Kaufman et al., 1993; Tisch et al., 1993).

Structural characterization of the immunodominant MBP(85–99) peptide identified residues critical for MHC class II binding and for T cell receptor (TCR) recognition (Wucherpfennig et al., 1994a). The MHC class II and TCR contact residues of the immunodominant MBP(85–99) peptide were then subjected to mutational analysis in order to define the set of amino acids permitted at each critical position. These structural criteria, together with the knowledge that amino acid side chains required for binding to MHC molecules are degenerate, were used to search a protein sequence data base. Selected viral and bacterial peptides were tested for their ability to activate...
human MBP(85–99)-specific T cell clones that had been established from blood T cells of MS patients. Of 129 peptides synthesized, seven viral peptides and one bacterial peptide that met the criteria were found to efficiently stimulate MBP-specific T cell clones. These viral and bacterial peptides therefore act as molecular mimics of the immunodominant MBP(85–99) peptide. Molecular mimicry of this immunodominant self-peptide by viruses therefore presents a possible mechanism for the induction of autoimmunity in MS.

Results

Structural Characterization of the Immunodominant T Cell Epitope of Human MBP

Susceptibility to MS is associated with HLA-DR2 (DRA, DRB1*1501, the most common subtype of DR2) (Spieelman and Nathenson, 1982; Olerup et al., 1989). This MHC class II molecule may play a critical role in the immunopathogenesis of MS by presenting immunodominant self-peptides to autoreactive T cells. Following injection of MBP in experimental animals, T cells specific for immunodominant peptides of MBP mediate an inflammatory response in the CNS that can be accompanied by marked demyelination (reviewed by Zamvil and Steinman, 1990). In previous studies, two regions of human MBP were found to be immunodominant (residues 84–102 and 143–168) (Ota et al., 1990; Pette et al., 1990; Martin et al., 1990; Wucherpfennig et al., 1994a). Reactivity to the MBP(84–102) peptide was predominantly seen in subjects carrying HLA-DR2. Using L cell transfectants as antigen-presenting cells, HLA-DR2b (DRA, DRBl*1501) was found to be immunodominant (residues 84–102 and 143–168) (Ota et al., 1990; Pette et al., 1990; Martin et al., 1990; Wucherpfennig et al., 1994a). Reactivity to the MBP(84–102) peptide bound with high affinity to the HLA-DR2b molecule with two hydrophobic residues serving as the primary anchors (Val-89 and Phe-92) (MBP(85–99) peptide) (Figure 1) (Wucherpfennig et al., 1994a; Vogt et al., 1994). At the first anchor position, Val-89 could be substituted by other aliphatic amino acids (leucine and isoleucine), as well as by methionine and phenylalanine; alanine was tolerated at this position but reduced the affinity of the peptide for HLA-DR2b. At the second anchor position, all aliphatic and aromatic residues were permitted; again alanine was tolerated but resulted in a loss of binding affinity.

A mutational analysis of putative TCR contact points demonstrated that Phe-91 and Lys-93 were the primary TCR contacts for the MBP(85–99)-specific clones; other residues such as Val-88 and His-90 were important for some clones but not for others. Substitution of Phe-91 by alanine abolished TCR recognition for all clones; some clones tolerated conservative substitutions (e.g., tyrosine or aliphatic amino acids) while other clones did not. Substitution of Lys-93 by arginine was tolerated by most T cell clones, but more drastic changes frequently resulted in a partial or complete loss of T cell reactivity. This analysis demonstrated that His-90, Phe-91, and Lys-93 were the primary TCR contact residues, while Val-89 and Phe-92 were the primary MHC contact residues (Figure 1).

Can Structural Motifs Be Used to Identify Viral Peptides That Activate MBP-Specific T Cells?

Based on this structural characterization of the immunodominant MBP(85–99) peptide, a set of structural criteria (i.e., a molecular mimicry motif) was developed to search a protein database for viral and bacterial sequences that fit these criteria. The different sets represent search criteria for different sets of clones with different preferences at TCR contact points (Val-88, His-90, Phe-91, and Lys-93). Hydrophobic amino acids (aliphatic and/or aromatic) were specified for the two major MHC anchor residues (Val-89 and Phe-92). The following number of peptides were synthesized for each set: set 1, 24 peptides; set 2, 46 peptides; set 3, 59 peptides. Random peptide sequences would be expected to match the motifs at the following frequencies: set 1, 1:40,000; set 2, 1:27,750; set 3, 1:3692 sequences.

Figure 1. Peptide Motifs Required for MHC Class II Binding and TCR Recognition of the Immunodominant MBP(85–99) Peptide

The MBP(88–97) segment is critical for MHC class II binding and TCR recognition by HLA-DR2- and HLA-DQ1-restricted clones. Peptide residues His-90, Phe-91, and Lys-93 appear to be critical TCR contacts for both sets of clones; hydrophobic amino acids are important for anchoring the peptide to the MHC class II molecules. Based on the recognition motifs and a detailed mutational analysis, molecular mimicry motifs were defined for searching a protein data base for viral and bacterial sequences that fit these criteria. The different sets represent search criteria for different sets of clones with different preferences at TCR contact points (Val-88, His-90, Phe-91, and Lys-93). Hydrophobic amino acids (aliphatic and/or aromatic) were specified for the two major MHC anchor residues (Val-89 and Phe-92). The following number of peptides were synthesized for each set: set 1, 24 peptides; set 2, 46 peptides; set 3, 59 peptides. Random peptide sequences would be expected to match the motifs at the following frequencies: set 1, 1:40,000; set 2, 1:27,750; set 3, 1:3692 sequences.
This was done since the MBP(85–99) peptide is presented by different HLA-DR2 subtypes: presentation by DRB1*1501 requires an aliphatic amino acid or phenylalanine at this position, while aliphatic and aromatic residues at this position can serve as anchor for DRB1*1602 (K. W. W. and J. L. S., unpublished data). This difference relates to the size of the primary pocket binding this hydrophobic residue and is determined by the Val/Gly dimorphism at DRβ86 (Val in *1501 and Gly in *1602) (Busch et al., 1991; Brown et al., 1993).

The third set represented a modification of the TCR contact residues preferred by a subgroup of MBP(85–99)-specific clones. For these clones, Lys-93 was absolutely conserved while Phe-91 could be substituted by some aromatic or aliphatic amino acids (Figure 1).

These search criteria also matched well with the structural requirements for a HLA-DQ1-restricted clone specific for the MBP(85–99) peptide. This clone required the same minimal peptide segment as DR2-restricted clones (residues 87–97). As in the DR2-restricted clones, His-90, Phe-91, and Lys-93 appeared to be the primary TCR contact residues (unpublished data). Based on pool sequencing of naturally processed peptides bound to HLA-DQ1, three hydrophobic positions (at position 1, 4, and 7 relative to the first anchor; Val-89, Phe-92, and Ile 95 in the MBP(85–99) peptide) are thought to contribute to binding (K. Falk and O. Rötschke, submitted). Substitution of these hydrophobic positions by aspartic acid greatly diminished the stimulatory capacity of the peptide, while substitutions by other hydrophobic amino acids were tolerated. These data suggest that the MBP(85–99) peptide is bound in a similar fashion to HLA-DR2b and HLA-DQ1 and that the same peptide residues are critical for interaction with the TCR.

These complex criteria were used to search protein data bases (PIR and SwissProt) using the Genetics Computer Group software (program: findpatterns). More than 600 sequences of viral and bacterial origin were identified that matched these criteria. From this pool, sequences were selected based on the following criteria: one, viruses known to cause human pathology; two, viruses prevalent in the Northern Hemisphere where MS occurs most frequently; three, selected bacterial sequences associated with inflammatory CNS disease (such as Borrelia burgdorferi) and with invasive infections (such as Staphylococcus aureus, Klebsiella pneumoniae, and Pseudomonas aeruginosa). Not included were most viruses that cause infections in tropical countries, sequences derived from vaccinia virus as well as a large number of sequences from Escherichia coli, which is part of the normal intestinal flora. When multiple antigenic variants were present, one or several sequences that best fit the search criteria were chosen. The selected peptides were synthesized by PinTechnology on a 1 mg scale (Chiron Mimotopes, San Diego); 70 peptides were made for criteria sets 1 and 2 (Figure 1) and 59 peptides for set 3.

**Activation of Human MBP(85–99)-Specific T Cell Clones by Viral Mimicry Peptides**

Peptides were tested for their ability to activate human MBP(85–99)-specific T cell clones that had been previously established from blood T cells of two patients with relapsing–remitting MS (Wucherpfennig et al., 1994a, 1994b). As previously, homozygous B cell lines that expressed DR2 (DRB1*1501 or DRB1*1602) or DQ1 were used as antigen-presenting cells in these T cell proliferation experiments (Wucherpfennig et al., 1994a). Seven clones were tested with the 70 viral/bacterial peptides from sets 1 and 2. As expected, all clones were activated by the MBP(85–99) peptide that served as the positive control.

Interestingly, three of the seven clones tested were also efficiently activated by several viral/bacterial peptides (Tables 1 and 2, data for five clones are shown). The first clone (Hy.1B11) recognized the MBP(85–99) peptide on HLA-DQ1; clones Hy.2E11 and Hy.1G11 were HLA-DR2 restricted (Wucherpfennig et al., 1994a). Among the first 70 peptides tested, three mimicry peptides stimulated the DQ1-restricted clone; two mimicry peptides from Epstein–Barr virus (EBV) and influenza type A virus stimulated two of the DR2-restricted T cell clones (Table 1). Among the second group of peptides (set 3, 59 peptides), one mimicry peptide from human papillomavirus was identified for the DQ1-restricted clone, while a reovirus peptide and a herpes simplex virus peptide were identified for the DR2-restricted clones (Hy.2E11 and Hy.1G11, respectively) (Table 2; data not shown). This second group of peptides has not yet been tested with the other DR2-restricted clones.

Taken together, the DQ1-restricted T cell clone recognized five structurally related peptides: the immunodominant MBP(85–99) peptide, three viral peptides (from herpes simplex, adenovirus type 12, and human papillomavirus) and a bacterial peptide (Pseudomonas aeruginosa). Two of the DR2-restricted clones were activated by four peptides. Both clones recognized the MBP(85–99) peptide as well as mimicry peptides from EBV and influenza virus. In addition, each clone recognized a viral peptide from reovirus (T cell clone Hy.2E11) and herpes simplex virus (clone Hy.1G11) (Table 2).

**Efficient T Cell Stimulation by Mimicry Peptides**

If viral/bacterial mimicry peptides are indeed important for the initiation of autoimmunity, they have to be capable of potent T cell stimulation that results in marked clonal expansion of autoaggressive T cell clones. The stimulatory capacity of the mimicry peptides was therefore compared with the MBP(85–99) peptide in a titration experiment (Figure 2). The peptides were found to be efficient stimulators of these MBP-specific T cell clones; in particular, the EBV peptide (DR2-restricted clones) and the adenovirus peptide (DQ1-restricted clone) were similar to the MBP(85–99) peptide in their stimulatory capacity. These results demonstrate that T cell mimicry is not the result of a minor degree of “cross-reactivity” but rather the result of structural similarity sufficient for potent T cell activation.

The efficient stimulation of MBP(85–99)-specific T cell clones by these peptides also argues against the presence of a small contaminating T cell population that responds to these peptides. To ensure that the peptides were indeed seen by a single T cell clone, both T cell clones were
Table 1. Screening of Five MBP (85–99)-Specific T Cell Clones for Reactivity to a Panel of Viral/Bacterial Mimicry Peptides

| Peptide Sequence Source | Hy.1B11 | Ob.1A12 | Ob.1C3 | Hy.2E11 | Hy.1G11 |
|-------------------------|---------|---------|--------|---------|---------|
| None                    | 6,090   | 420     | 452    | 1,471   | 200     |
| ENPVVHFFKVNVTPR         | 80,102  | 32,631  | 21,171 | 70,350  | 8,859   |
| Human papillomavirus     | 4,751   | 821     | 769    | 897     | 234     |
| Epstein–Barr virus       | 3,850   | 412     | 391    | 772     | 160     |
| Herpes simplex virus     | 20,164  | 426     | 402    | 981     | 157     |
| Parainfluenza virus type 2 | 4,889  | 393     | 443    | 531     | 178     |
| Human papillomavirus     | 4,344   | 529     | 436    | 821     | 197     |
| Picketta psoasaezid      | 5,443   | 547     | 436    | 2,502   | 219     |
| Yenista pseudotuberculosis | 4,902  | 414     | 442    | 924     | 143     |
| Cytomegalovirus          | 3,712   | 444     | 490    | 963     | 175     |
| Cytomegalovirus type 40 and 41 | 3,158 | 441     | 460    | 815     | 201     |
| Staphylococcus aureus    | 3,086   | 407     | 449    | 919     | 204     |
| Borelia burgdorferi      | 3,884   | 444     | 442    | 605     | 199     |
| Klebsiella pneumoniae    | 2,912   | 419     | 454    | 797     | 221     |
| Herpes simplex           | 4,628   | 430     | 400    | 1,053   | 193     |
| Varolite-Zoster virus    | 5,820   | 340     | 437    | 858     | 103     |
| Human cytomegalovirus    | 2,619   | 426     | 510    | 967     | 144     |
| Human papillomavirus     | 4,344   | 442     | 408    | 928     | 154     |
| Rickettsia prowazekii    | 5,448   | 547     | 436    | 2,502   | 219     |
| Yersinia pseudotuberculosis | 4,902  | 414     | 442    | 924     | 143     |
| Cytomegalovirus          | 3,712   | 444     | 490    | 963     | 175     |
| Epstein–Barr virus       | 5,443   | 547     | 436    | 2,502   | 219     |
| Herpes simplex           | 4,628   | 430     | 400    | 1,053   | 193     |
| Varolite-Zoster virus    | 5,820   | 340     | 437    | 858     | 103     |
| Human cytomegalovirus    | 2,619   | 426     | 510    | 967     | 144     |
| Human papillomavirus     | 4,344   | 442     | 408    | 928     | 154     |
| Rickettsia prowazekii    | 5,448   | 547     | 436    | 2,502   | 219     |
| Yersinia pseudotuberculosis | 4,902  | 414     | 442    | 924     | 143     |
| Cytomegalovirus          | 3,712   | 444     | 490    | 963     | 175     |
| Epstein–Barr virus       | 5,443   | 547     | 436    | 2,502   | 219     |
| Herpes simplex           | 4,628   | 430     | 400    | 1,053   | 193     |
| Varolite-Zoster virus    | 5,820   | 340     | 437    | 858     | 103     |
| Human cytomegalovirus    | 2,619   | 426     | 510    | 967     | 144     |
| Human papillomavirus     | 4,344   | 442     | 408    | 928     | 154     |
| Rickettsia prowazekii    | 5,448   | 547     | 436    | 2,502   | 219     |
| Yersinia pseudotuberculosis | 4,902  | 414     | 442    | 924     | 143     |
| Cytomegalovirus          | 3,712   | 444     | 490    | 963     | 175     |
| Epstein–Barr virus       | 5,443   | 547     | 436    | 2,502   | 219     |
| Herpes simplex           | 4,628   | 430     | 400    | 1,053   | 193     |
| Varolite-Zoster virus    | 5,820   | 340     | 437    | 858     | 103     |
| Human cytomegalovirus    | 2,619   | 426     | 510    | 967     | 144     |
| Human papillomavirus     | 4,344   | 442     | 408    | 928     | 154     |
| Rickettsia prowazekii    | 5,448   | 547     | 436    | 2,502   | 219     |
| Yersinia pseudotuberculosis | 4,902  | 414     | 442    | 924     | 143     |
| Cytomegalovirus          | 3,712   | 444     | 490    | 963     | 175     |
| Epstein–Barr virus       | 5,443   | 547     | 436    | 2,502   | 219     |
| Herpes simplex           | 4,628   | 430     | 400    | 1,053   | 193     |
| Varolite-Zoster virus    | 5,820   | 340     | 437    | 858     | 103     |
| Human cytomegalovirus    | 2,619   | 426     | 510    | 967     | 144     |

recloned by limiting dilution. The subclones had the same specificity for MBP(85–99) and for the viral peptides as the parental T cell clones. Two subclones were obtained for Hy.1B11 (DQ1 restriction); these reacted with the MBP(85–99) peptide as well as with the herpesvirus, adenovirus, and Pseudomonas peptides (the papillomavirus peptide from the second synthesis was not tested on the subclones). One subclone was obtained for Hy.2E11 (DR2 restriction); this clone reacted with MBP(85–99) as well as with the EBV and the influenza peptides as did the parental clone (the reovirus peptide from the second synthesis was not tested). In addition, previous polymerase chain reaction (PCR) analysis of these T cell clones using a panel of TCR Va and V13 family-specific primers had indicated that they represented clonal populations (Wucherpfennig et al., 1994b). Surface staining of clone Hy.1G11 with a monoclonal antibody specific for the V1317.1 segment (MAb C1, Friedman et al., 1991) showed that all cells expressed the V1317.1 segment, proving that it represented a clonal population.

Mimicry Peptides Have Conserved Features but Are Quite Distinct from the MBP Peptide

Comparison of peptide sequences that stimulate the same TCR revealed several interesting points. First, only one peptide (from human papillomavirus L2 protein) had striking sequence similarity with the MBP(85–99) peptide, in that all amino acids in the MBP(89–95) segment except position 94 (asparagine to aspartic acid) were identical (Table 2). For all other sequences, simple alignment would not have predicted them to be efficient stimulators of MBP(85–99)-specific T cell clones. Second, at positions not specified by the search criteria, the selection for particular amino acids was apparent (Table 2). For example, for the DQ1-restricted clone, aspartic acid was selected at position 94 (probably a TCR contact) in all four mimicry peptides. This position is occupied by asparagine in the MBP peptide (similar size, but no negative charge). Substitution of Asn-94 for aspartic acid markedly increased its stimulatory capacity for the DQ1-restricted clone but reduced it for the DR2-restricted clone. Selection also oc-
Table 1. (continued)

| Peptide Sequence | Source | Hy.1B11 | Ob.1A12 | Ob.1C3 | Hy.2E11 | Hy.1G11 |
|------------------|--------|---------|---------|--------|---------|---------|
| 42 RTLVLAFVKTCVLA | Adenovirus type 2 | 3,756 | 405 | 400 | 962 | 156 |
| 43 TLMVIFPVKLVYADIT | Coxackie A9 virus | 3,411 | 427 | 451 | 744 | 188 |
| 44 VEGATFLKNNPFAF | Human cytomegalovirus | 3,137 | 426 | 458 | 786 | 148 |
| 45 VGGVSVLKNPFGGG | Human herpesvirus 6 | 3,710 | 349 | 469 | 774 | 193 |
| 46 DSIFLICFYRGEGLS | Human cytomegalovirus | 3,936 | 371 | 416 | 1,332 | 203 |
| 47 VNLLEFLKDWSHGL | Epstein-Barr virus | 3,913 | 371 | 410 | 1,088 | 201 |
| 48 IANTVLCFVSGIILLY | Hepatitis A virus | 4,472 | 374 | 439 | 1,088 | 197 |
| 49 GFAALFYKHGFNSS | Hepatitis C virus | 4,180 | 397 | 418 | 1,332 | 168 |
| 50 GFLAALFYKHFKNAS | Hepatitis C virus | 3,581 | 360 | 468 | 987 | 202 |
| 51 YRNLFVFKVGNSYP | Influenza A virus | 3,382 | 371 | 399 | 567 | 183 |
| 52 YRNLFVF1KNTRYTP | Influenza A virus | 3,911 | 368 | 420 | 45,094 | 5,885 |
| 53 DLRLVSLF1KGTKVVP | Influenza A virus | 4,315 | 406 | 414 | 438 | 214 |
| 54 SGLR1FLKDV1ESM | Influenza A virus | 3,882 | 380 | 498 | 720 | 205 |
| 55 GEL1FLFKNGLSA | Influenza C virus | 4,908 | 365 | 428 | 884 | 161 |
| 56 VLALIFTFKTALAP | Japanese encephalitis virus | 11,189 | 329 | 415 | 1,128 | 159 |
| 57 IQLQVLSFFGKTIING | Newcastle disease virus | 3,895 | 389 | 392 | 1,121 | 195 |
| 58 CAMVRFYYRQMQRE | Human papillomavirus | 3,428 | 365 | 410 | 587 | 161 |
| 59 NSANAAFLKNSNSQAK | Human papillomavirus | 3,698 | 433 | 476 | 685 | 189 |
| 60 TLDL1FLFLTFGGGLL | Parainfluenza virus type 3 | 4,138 | 399 | 499 | 708 | 206 |
| 61 DLPMVTFLKDELIRK | Rhinovirus type 89 | 4,375 | 365 | 426 | 453 | 211 |
| 62 PAAALAFKTYNLPV | Sindbis virus | 4,156 | 404 | 443 | 571 | 200 |
| 63 DTKLAGFLKHYNSW | Rotavirus | 4,185 | 398 | 376 | 775 | 169 |
| 64 FVILVPIFKQNYQJ | Rotavirus | 4,350 | 399 | 468 | 1,015 | 212 |
| 65 YARVIFDFAXRE1AD | Campylobacter jejuni | 2,769 | 379 | 447 | 1,034 | 181 |
| 66 EQFKAHYFRVTGKE | Hemophilus influenza | 2,961 | 312 | 392 | 828 | 132 |
| 67 PRAAALAFKFCNAL | Klebsiella | 5,096 | 355 | 364 | 631 | 134 |
| 68 ERFARFVYVQGRPA | Pseudomonas aeruginosa | 4,894 | 350 | 374 | 899 | 143 |
| 69 APAGALFAAKHEVIG | Pseudomonas aeruginosa | 3,965 | 390 | 305 | 983 | 163 |
| 70 DRLLMFLKDVVSRN | Pseudomonas aeruginosa | 3,827 | 311 | 373 | 887 | 169 |
| 71 NQEAAG1FKHEQLL | Staphylococcus aureus | 3,830 | 345 | 413 | 956 | 202 |
| 72 EKLLAFAKADKTYES | Streptococcus pneumoniae | 4,916 | 325 | 445 | 1,061 | 191 |

The MBP(85–99) peptide (peptide 2) was used as a positive control; mimicry peptides 3–26 were from peptide set 1, mimic peptide 27–72 from peptide set 2. T cell clone Hy.1B11 is HLA-DQ1 restricted, clones Ob.1A12, Ob.1C3, Hy.2E11, and Hy.1G11 are HLA-DR2 restricted. Irradiated homozygous B cell lines were used as antigen-presenting cells: 9001 (DQ1) for clone Hy.1B11; MGAR (DR2 [DRB1*1501]) for clones Ob.1A12, Ob.1C3, Hy.2E11, and Hy.1G11. B cells were pulsed with peptides for 2 hr at a concentration of approximately 60 µg/ml (clones Hy.1B11, Ob.1A12, and Hy.1G11) and at approximately 12.5 µg/ml for clones Ob.1C3 and Hy.2E11. After the 2 hr pulse, T cells were added (50 x 10⁴/ml well; final peptide concentrations: 12.5 µg/ml and 3.1 µg/ml, respectively). Numbers represent incorporation of [3H]thymidine that was determined after a 3 day culture period. Two other T cell clones (Hy.2B6 and Ob.3D1) were also tested and responded only to the MBP(85–99) peptide (data not shown).

The majority of the viruses are common human pathogens: influenza type A frequently causes respiratory tract infections; human papillomavirus infects epithelial tissues and has been linked to cervical carcinomas; EBV causes an acute viral syndrome (infectious mononucleosis) in young adults. Human herpesvirus I (herpes simplex), EBV, and human papillomavirus cause latent/persistent infections; the respective reservoirs are neurons (herpes simplex), B cells (EBV), and epithelial cells (papillomavirus). Virus expression can be reactivated by UV exposure and stress (herpes simplex) and by B cell activation (EBV) (Schwarz et al., 1985; Epstein and Achong, 1977; Spruance, 1985; Tovey et al., 1978). For the induction and maintenance of an autoimmune response, these persistent viral infections are of particular interest as they could explain the chronicity of the clinical disease and the clonal expansion and persistence of MBP-specific T cells. Reactivation of viral expression may also be involved in triggering clinical relapses. By this mechanism, viral mimicry peptides could activate resting MBP-specific T cells in periphery and allow them to invade the CNS (Figure 4).
Viral Variants Differ in Their Capacity to Activate MBP-Specific T Cell Clones

Two peptides from different strains of influenza type A matched the initial search criteria; only one of them was not transcribed in this latent state; however, B cell activation results in activation of the lytic cycle and in the expression of the DNA polymerase gene (Datta et al., 1980). To examine MHC class II-restricted presentation of the EBV DNA polymerase, an HLA-DR2 + EBV-transformed B cell line (MGAR) and an MHC-mismatched control (9001, HLA-DR1) were pretreated for 36 hr with phorbol ester, which was removed by extensive washing prior to coculture of antigen-presenting cells infected with the virus. In vivo, this recognition event could lead to chronic antigenic stimulation of MBP-specific T cells as B cell activation results in the reexpression of EBV genes, including the DNA polymerase gene.

Table 2. Sequence Alignment of Viral/Bacterial Mimicry Peptides That Stimulate MBP-Specific T Cell Clones That Are DQ1 or DR2 Restricted

| Peptides Recognized by Clone Hy.1B11 (DQ1 Restricted) | Peptide Concentration (pg/ml) |
|--------------------------------------------------------|-----------------------------|
| MBP(85–99)                                              | 85  90  94  99              |
| Herpes simplex, UL15 protein                            | ENPVHFFKNIIVTPR             |
| Adenovirus type 12, ORF                                  | FRQLVHVRFDQALL             |
| Pseudomonas, phosphomannomutase                          | DPEVTFKDVLPF               |
| Human papillomavirus type 7, L2 protein                  | DRLMLFSDKDVSRN             |
|                                                        |                             |
| Peptides Recognized by Clone Hy.2E11 (DR2 Restricted)   |                             |
| MBP(85–99)                                              | 85  90  94  99              |
| EBV, DNA polymerase                                      | ENPVHFFKNIIVTPR             |
| Influenza type A, hemagglutinin                          | YRNLVFIKKNTRYP             |
| Reovirus type 3, sigma 2 protein                         | MARAAFLFKTVGFGG             |
|                                                        |                             |
| Peptides Recognized by Clone Hy.1G11 (DR2 Restricted)   |                             |
| MBP(85–99)                                              | 85  90  94  99              |
| EBV, DNA polymerase                                      | ENPVHFFKNIIVTPR             |
| Influenza type A, hemagglutinin                          | YRNLVFIKKNTRYP             |
| Herpes simplex, DNA polymerase                          | GGRRLLFVKAVHRES             |

Only the human papillomavirus peptide has obvious sequence similarity with the MBP(85–99) peptide (residues identical in the 89–95 segment are underlined). All mimicry peptides that stimulate the DQ1-restricted clones have aspartic acid (D) at position 94 (a putative TCR contact); hydrophobic residues were selected at position 95 (a putative MHC contact). In contrast, two of three mimicry peptides for the DR2-restricted clones have a positive charge (lysine) at position 94.

Figure 2. Efficient Stimulation of MBP(85–99)-Specific Clones by Mimicry Peptides

Peptides were compared with the MBP(85–99) peptide in a titration experiment. The top panel shows the DR2-restricted clone (Hy.2E11) with MGAR (DQB1*1501) as antigen-presenting cells, while the bottom panel shows the DQ1-restricted clone (Hy.1B11) with 9001 (DQ1) as antigen-presenting cells. B cells were pulsed with peptides for 2 hr, washed, and cocultured with T cells for 3 days. Numbers represent cpm of incorporated [3H]thymidine as a measure of T cell proliferation.

The observation that certain viral strains are capable of stimulating clone Hy.2E11. These two viral sequences were derived from the hemagglutinin subtype H13 (there are 13 serologically defined hemagglutinin subtypes of influenza type A) (Chambers et al., 1969). These hemagglutinin peptides differed at four positions: the first substitution was at position 92 (isoleucine for valine), which anchors the peptide to DR2; the other substitutions were at positions 95–97 (Table 3). Single amino acid substitutions demonstrated that the change at position 97 (arginine to serine) was responsible for the loss of reactivity (Table 3). This was surprising since threonine is present in the MBP peptide position 97 was not subject to strong selection (G2a.5). These results demonstrate that the MBP-specific T cell clones recognize not only the viral peptide but also antigen-presenting cells infected with the virus. In vivo, this recognition event could lead to chronic antigenic stimulation of MBP-specific T cells as B cell activation results in the reexpression of EBV genes, including the DNA polymerase gene.

Viral Variants Differ in Their Capacity to Activate MBP-Specific T Cell Clones

Two peptides from different strains of influenza type A matched the initial search criteria; only one of them was stimulatory for clone Hy.2E11. These two viral sequences have threonine at serine position 97 (arginine to serine) and since the change at position 97 (arginine to serine) was responsible for the loss of reactivity (Table 3). This was surprising since threonine is present in the MBP peptide position 97 was not subject to strong selection among the mimicry peptides (the stimulatory peptides have threonine, histidine, arginine, or phenylalanine at this position). Therefore, it is likely that this substitution affects the overall peptide conformation as described for MHC class I-bound peptides (Madden et al., 1993). These effects on the overall peptide conformation are probably responsible for the fact that the majority of viral peptides do not stimulate MBP-specific T cells while other strains are...
not may be important in defining the epidemiology of the disease. “Epidemic” outbreaks of MS have been noted (for example on the Faroe islands [Kurtzke and Hyllestad, 1979]) that may be related to particular viral strains that possess strongly cross-reactive T cell epitopes. These results also indicate that epidemiological studies will have to take viral subtypes and viral antigenic variation into account. Influenza viruses are among the interesting candidates as presentation of the influenza hemagglutinin (from which the mimicry peptide is derived) by MHC class II molecules is well documented [Brown et al., 1991].

**MBP(85-99) and Its Viral Mimicry Peptides Are Efficiently Presented by the Disease-Associated DR2 Molecule**

The presentation of the viral mimicry peptides by different DR2 subtypes was compared to determine whether they are efficiently presented by the disease-associated molecule (DRB1*1501, the most common DR2 subtype). The MBP peptide was presented by three of the four DR2 subtypes; the peptide was not presented by DRB1*1601, which differs from DRB1*1602 by a single amino acid substitution (at position DRI67, a possible TCR contact). The two viral peptides were presented much better by the DR15 molecules (DRB1*1501 and 1502, which differ only at position DR186) than by DRB1*1602. This was particularly evident for the influenza peptide, which only activated T cell clone when presented by the DRB1*1501/1502 molecules but not by DRB1*1602 (Table 4). These results indicate that the viral mimicry peptides identified here are more efficiently presented by the MS-associated DR2 molecules (DRB1*1501/1502).

**Discussion**

This study establishes that some TCRs actually recognize not a single peptide but rather a limited repertoire of structurally related peptides derived from different antigens. This was true for three of the seven MBP(85–99)-specific T cell clones studied. One of these clones recognized five different peptides; the other clone recognized four peptides from different antigens. This recognition did not merely represent a minor degree of cross-reactivity, since these peptides efficiently activated the MBP(85–99)-specific clones. The other T cell clones were probably negative because the search criteria had focused only on the core region of the peptide (residues 88–93) that contained the most important MHC and TCR contact points common to all clones. Several clones for which no mimicry peptides were identified do, however, need a longer peptide segment than the positive clones (residues 85–97 versus residues 87–97). It is therefore likely that mimicry peptides could also be identified for these clones if all positions of the peptide were subjected to a detailed mutational analysis. As only a small fraction of the peptides that matched the criteria were synthesized, it is likely that many more peptides capable of activating MBP(85–99)-specific T cells could be identified.
It was, however, surprising that the majority of peptides did not result in T cell activation. Most likely, amino acid substitutions at single positions have only limited predictive value as the simultaneous substitution of multiple positions may profoundly affect the peptide conformation. This has been elegantly demonstrated for neighboring positions (Table 3).

Table 3. Antigenic Variation of Viral Epitopes Determined Capacity for T Cell Stimulation by Molecular Mimicry

| Methylated peptide | DRB*1501 | DRB*1502 | DRB*1601 | DRB*1602 |
|--------------------|----------|----------|----------|----------|
| No peptide         | 310      | 1,064    | 390      | 423      |
| MBP(86-99)         | 11,487   | 10,189   | 601      | 14,557   |
| Influenza peptide 52 | 12,005   | 11,277   | 521      | 3,389    |
| Influenza peptide 51 | 5,266    | 10,079   | 458      | 412      |
| Influenza peptide 52 (96 Asn) | 805      | 16,070   | 13,998   | 14,884   |
| Influenza peptide 52 (95 Gly) | 20,116   | 20,116   | 20,116   | 20,116   |
| Influenza peptide 52 (97 Ser) | 1,299    | 1,299    | 1,299    | 1,299    |
| No peptide         | 310      | 1,064    | 390      | 423      |

Two influenza type A hemagglutinin peptide sequences obtained from different viral isolates matched the search criteria, one of these sequences stimulated the DR5-restricted clone, the other peptide did not. Using single amino acid substitutions of the four positions different between these two peptides, the predictive stimulation of peptide 51 was mapped to position 97 (Arg to Ser). These results indicate that antigenic variation of viruses can have a profound influence on molecular T cell mimicry. Numbers represent cpm of incorporated [3H]thymidine as a measure of T cell proliferation (mean of triplicates).

Cross-reactivity is part of the positive selection process in the thymus that selects T cells with low affinity for self-MHC molecules (plus peptide) and deletes T cells with higher affinity for their ligand (Kappler et al., 1987; Kieselow et al., 1988; Sebzda et al., 1994). The relatively high frequency of alloreactive T cells also indicates that T cell recognition is not absolutely specific. Cytotoxic T cells specific for an EBV peptide bound to I-A\*DQ6 were found to cross-react with HLA-B44 (Burrows et al., 1994). This alloreactivity is probably the result of molecular mimicry between the HLA-B8-bound EBV peptide and a HLA-B44-bound self-peptide that remains to be identified.

Molecular mimicry may also be an important mechanism in experimental autoimmune diseases. Immunization of Lewis rats with complete Freund's adjuvant induces a strong T cell response to a mycobacterial heat shock protein 65 (hsp65) peptide. Hsp65-reactive T cell clones mediate arthritis by cross-reacting with a joint proteoglycan (van Eden et al., 1985, 1988). While the cross-reacting joint peptide remains to be biochemically defined, molecular mimicry between hsp65 and a joint proteoglycan appears to be the underlying pathogenetic mechanism. Significant sequence similarity had also been noted between a T cell epitope of rabbit MBP and hepatitis B virus. Administration of this hepatitis B virus peptide was found to induce histological signs of CNS inflammation and T cell reactivity to MBP in a polyclonal population (Fujinami and Oldstone, 1986).

The diverse nature of the molecular mimicry peptides and the ubiquitous presence of some of these pathogens may make it difficult to establish a direct epidemiological relationship.
The link between these viral infections and the occurrence of MS. In addition, the temporal relationship between a viral infection and the initiation of MS is not clear in most cases, as the clinical diagnosis is frequently made at a time when magnetic resonance scans demonstrate a relatively large number of old lesions (Stadt et al., 1990). It may, however, be possible to directly demonstrate the causal relationship in patients with postinfectious encephalomyelitis by establishing both virus-specific and MBP-specific T cell clones. The importance of molecular mimicry could also be demonstrated in MS patients with a recent viral infection (high IgM antibody titers to a particular virus) and magnetic resonance scans indicative of a recent onset of disease.

The diverse nature of the viral peptides that stimulate MBP(85–99)-specific T cell clones makes it unlikely that a single virus is responsible for initiating autoimmunity in MS. The observation that several pathogens carry mimicry epitopes of MBP(85–99) could explain why it has been so difficult to link the immunopathogenesis of MS to a single viral agent. Rather, it appears that a group of common viral pathogens, in particular the herpes virus family (EBV, herpes simplex, and cytomegalovirus), influenza viruses, and papillomaviruses could be involved in initiating the autoimmune process. This notion is supported by clinical and epidemiological data that suggest the involvement of several pathogens; the observation that oligoclonal immunoglobulins in the cerebrospinal fluid of MS patients are specific for several different viruses also points in this direction (Kurtzke, 1985; Baig et al., 1989). Childhood immunization with viral pathogens that carry mimicry T cell epitopes may reduce the risk of developing MS later in life. Genetic modifications of viral vaccines that eliminate proven mimicry epitopes could make viral vaccines safer and reduce the frequency of postvaccinal encephalomyelitis.

Experimental Procedures

Cell Lines

Homozygous EBV-transformed B cell lines used were the following: MGAR (DRB1*1501), 9011 (DRB1*1502), 9009 (DRB1*1501), 9016 (DRB1*1602), and 9001 (DQA1*0101, DQB1*0501). The importance of molecular mimicry could also be demonstrated in MS patients with a recent viral infection (high IgM antibody titers to a particular virus) and magnetic resonance scans indicative of a recent onset of disease.

Cell Lines

Homozygous EBV-transformed B cell lines used were the following: MGAR (DRB1*1501), 9011 (DRB1*1502), 9009 (DRB1*1501), 9016 (DRB1*1602), and 9001 (DQA1*0101, DQB1*0501).

Peptide Synthesis

Mimicry peptides were synthesized on a 1 mg scale using the Multipin Peptide Synthesis System (Chiron Mimotopes). Peptides were synthesized on pins with a cyclic dipeptide (diketopiperazine, DKP) group attached to the C-terminus of the peptide that allowed cleavage in aqueous solution at a neutral or slightly basic pH. Peptide synthesis was monitored by including a standard peptide sequence as a control, which was subjected to HPLC and mass spectroscopy analysis. The immunodominant MBP(85–99) peptide was also included as a positive control for the T cell experiments.

Pin peptides were lyophilized and reconstituted at a concentration of 2 mg/ml in 40% acetonitrile, 10 mM HEPES (pH 7.4). These conditions allowed the majority of peptides to be completely solubilized. Preliminary experiments had indicated that adding acetonitrile to a final concentration of 2% or less had no detrimental effect on the degree of T cell stimulation observed in the proliferation assay.

Viral and bacterial peptides that stimulated MBP(85–99)-specific clones were resynthesized by conventional methods (free C-terminus instead of the DKP group); the identity of peptides was further confirmed by mass spectroscopy (using a API III Sciex Ionspray Spectrometer) and by amino acid analysis.

Cloning of MBP(84–102)-Specific T Cells

Previously established MBP-specific T cell clones specific for the immunodominant MBP(85–99) peptide were used in this study (Wucherpfennig et al., 1994a, 1994b). These clones had been generated from blood mononuclear cells of two patients with relapsing-remitting MS carrying HLA-DR2 (DR2 subtypes: DRB1*1501 for patient Ob, DRB1*1602 for patient Hy). In both patients, the T cell response was focused on the immunodominant MBP(84–102) peptide. T cell lines specific for MBP had been generated from blood mononuclear cells by stimulation with MBP (100 ng/ml) in RPMI 1640 supplemented with 10% human serum, 2 mM L-glutamine, 10 mM HEPES, 100 μg/ml penicillin/streptomycin in 96-well plates at 2 x 10⁵ cells/well (Ofa et al., 1990). On day 3, IL-2 was added to 5% (Human T-Stim, Becton Dickinson, Bedford, MA). On day 14, an aliquot of each cell line was assayed for reactivity to human MBP followed by proliferation assays with a panel of 13 synthetic peptides encompassing the human MBP sequence. Following a third round of stimulation (generally two stimulations with MBP and one stimulation with peptide), T cell lines were cloned by limiting dilution using allogeneic feeder cells and phytohemagglutinin (PHA) (1 μg/ml) (Murex Diagnostics, Dartford, England) for stimulation. Allogeneic MNC were irradiated with 5000 rad and cocultured in 96-well plates (2 μg/well) with T cells. IL-2 was added on day 3, and cells were fed every 3–4 days with media containing 5% IL-2-containing supernatant. On day 12–14, growth-positive wells were expanded by restimulation with PHA, IL-2, and allogeneic feeder cells.

Recloning of MBP-specific clones was also done by limiting dilution using allogeneic feeder cells, PHA, and recombinant human IL-2 (Boehringer Mannheim). Clones were maintained by weekly stimulation with irradiated allogeneic feeder cells, PHA, and rIL-2. Alternatively, clones were expanded by stimulation with MBP(85–99) peptide-pulsed B cells and rIL-2.

T Cell Proliferation Assays

T cell proliferation assays were done using EBV-transformed homozygous B cell lines as antigen-presenting cells. B cells were irradiated (5000 rad) and pulsed with peptide for 2 hr prior to addition of T cells. For screening of pin-peptides, 25 x 10⁵ B cells were added per well of a 96-well microtiter plate in a 50 μl volume (in triplicates). Peptide was added to a concentration of approximately 60 μg/ml. Following a 2 hr incubation at 37°C/5% CO₂, 50 x 10⁵ T cells were added to a total culture volume of 200 μl/well (final peptide concentration: approximately 12.5 μg/ml). After 3 days, T cell proliferation was determined with a [³H]thymidine pulse (1 μCi/well) and liquid scintillation counting.

For MHC restriction experiments, irradiated B cells were pulsed with peptide for 2 hr at 37°C, followed by extensive washing. Peptide-pulsed B cells (25 x 10⁵) were cocultured with 50 x 10⁵ T cells for 3 days; T cell proliferation was determined with a [³H]thymidine pulse (1 μCi/well) and liquid scintillation counting.

Acknowledgments

The authors wish to thank Anne L. Wucherpfennig and Mike Farzan for help with the data base searches and Basya Rybalov for expert technical assistance. We acknowledge the important contribution that Dr. David Hafler and members of his laboratory have made toward the generation of the T cell clones used in this study. This work was supported by grants from the National Multiple Sclerosis Society and the National Institutes of Health (CA47554 and NO1.AI.45198). K. W. W. is a Harry Weaver Neuroscience Scholar of the National Multiple Sclerosis Society.

Received November 15, 1994; revised December 15, 1994.

References

Allegretta, M., Nicklas, J. A., Strim, S., and Albertini, R. J. (1990). T cell responses to myelin basic protein in patients with multiple sclerosis. Science 247, 716–721.

Baig, S., Olsson, C., Olsson, T., Love, A., Jeansson, S., and Link, H. (1989). Cells producing antibody to measles and herpes simplex virus in cerebrospinal fluid and blood of patients with multiple sclerosis...
controls. Clin. Exp. Immunol. 78, 390–395.

Brooke, S., Gaur, A., Piercy, C., Gautam, A., Gibbels, K., Fathman, C. G., and Steinman, L. (1993). Induction of repressing parasitism in experimental autoimmune encephalomyelitis by bacterial superantigen. Nature 365, 642–644.

Brown, L. R., Nygard, N. R., Graham, M. B., Bono, C., Braciale, V. L., Gorka, J., Schwartz, B. D., and Braciale, T. J. (1991). Recognition of the influenza hemagglutinin by class II MHC-restricted T lymphocytes and antibodies. I. Site definition and implications for antigen presentation and T lymphocyte recognition. J. Immunol. 147, 2677–2684.

Brown, J. H., Jardelevsky, T. S., Fainberg, L. J., Stein, J. L., Urban, R. G., Strominger, J. L., and Wiley, D. C. (1993). Three-dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 364, 33–39.

Burns, J., Rosenzweig, A., Zveiman, B., and Lisak, R. P. (1983). Isolation of myelin basic protein–reactive T-cell lines from normal human blood. Cell. Immunol. 81, 435–440.

Burns, S. R., Khatru, R., Burrows, J. M., and Moss, D. J. (1994). An allosreactor in humans is dominated by cytotoxic T lymphocytes (CTL) clones cross-reactive with a single Epstein–Barr virus (EBV) CTL epitope: implications for graft-versus-host disease. J. Exp. Med. 179, 1156–1161.

Busch, R., Hill, C. M., Hayball, J. D., Lamb, J. R., and Rothbard, J. B. (1991). Effect of a natural polymorphism at residue 86 of the HLA-DR B locus on T cell binding. J. Immunol. 147, 1290–1298.

Chambers, T. M., Yamnikova, S., Kawaoka, Y., Lvsch, D. K., and Webber, R. G. (1989). Antigenic and molecular characterization of subtype H13 hemagglutinin of influenza virus. Virology 172, 180–188.

Cole, B. C., and Griffiths, M. M. (1993). Triggering and exacerbaration of autoimmune arthritis by the mycoplasma arthritidis superantigen MAM. Arthritis Rheum. 36, 994–1002.

Conrad, B., Weidmann, E., Trucuo, G., Rudert, W. A., Bebloo, R., Ricord, C., Rodriguez-Rizo, H., Fencgold, D., and Trucuo, M. (1994). Evidence for superantigen involvement in insulin-dependent diabetes mellitus aetiology. Nature 371, 351–355.

Datta, A. K., Feighn, R. J., and Pagano, J. S. (1980). Induction of Epstein–Barr virus-associated DNA polymerase by 72-0-kinase. Proc. Natl. Acad. Sci. USA 77, 5120–5125.

Epstein, M. A., and Aclong, B. G. (1977). Pathogenesis of infectious mononucleosis, Lancet ii, 1270–1272.

Friedman, S. M., Crow, M. K., Tumang, J. R., Tumang, M., Xu, Y., Ricord, C., Feighn, D., and Pagano, J. S. (1980). Induction of EB virus antibody responses in juvenile-onset diabetes mellitus. Clin. Endocrinol. 12, 372–375.

Fujinami, R. S., and Oldstone, M. A. (1985). Amino acid homology of the influenza hemagglutinin with myelin basic protein and virus: a mechanis for autoimmuneity. Science 230, 1043–1045.

Hickey, W. H., Hsu, B. L., and Kimura, H. (1991). T-lymphocyte entry into the central nervous system. J. Neurosci. Res. 28, 254–260.

Johnson, R. T., Griffin, D. E., Hirsch, J. S., Wolinsky, J. S., Rodenberg, S., Lindo De Soriano, I., and Vialsberg, A. (1984). Measles encephalomyelitis: clinical and immunological studies. N. Engl. J. Med. 310, 1371–1411.

Kappler, J. W., Rohem, N., and Marrack, P. (1987). T cell tolerance by clonal elimination in the thymus. Cell 49, 273–280.

Kaufman, D. L., Clare-Salzter, M., Tian, J., Forsthuber, T., Ting, G. S. P., Robinson, P., Atkinson, M. A., Sercarz, E. E., Tobin, A. J., and Lehmann, P. V. (1993). Spontaneous loss of T-cell tolerance to glutamic acid decarboxylase in murine insulin-dependent diabetes. Nature 366, 69–72.

Kieslow, P., Teh, H. S., Bluthmann, H., and von Boehm, H. (1988). Positive selection of antigen-specific T cells in thymus by restricting MHC molecules. Nature 335, 730–733.

Kurtzke, J. F. (1985). Epidemiology of multiple sclerosis. In Handbook of Clinical Neurology. P. J. Vinken, G. W. Bruyn, H. L. Klawane, and J. C. Koetsier, eds. (New York: Elsevier Science Publishing), pp. 259–287.
Molecular Mimicry in T Cell–Mediated Autoimmunity

van Eden, W., Thole, J. E. R., van der Zee, R., Noordzij, A., van Embden, J. D. A., Hensen, E. J., and Cohen, I. R. (1988). Cloning of the mycobacterial epitope recognized by T lymphocytes in adjuvant arthritis. Nature 331, 171–173.

Vogt, A. B., Kropshofer, H., Kalbacher, H., Kalbus, M., Rammensee, H.-G., Colligan, J. E., and Martin, R. (1994). Ligand motifs of HLA-DRB5*0101 and DRB1*1501 molecules delineated from self-peptides. J. Immunol. 151, 1665–1673.

Wekerle, H., Linington, C., Lassmann, H., and Meyermann, R. (1986). Cellular immune reactivity within the CNS. Trends Neurosci. 9, 271–277.

Wucherpfennig, K. W., Weiner, H. L., and Hafler, D. A. (1991). T-cell recognition of myelin basic protein. Immunol. Today 12, 277–282.

Wucherpfennig, K. W., Sette, A., Southwood, S., Oseroff, C., Matsui, M., Strominger, J. L., and Hafler, D. A. (1994a). Structural requirements for binding of an immunodominant myelin basic protein peptide to DR2 isotypes and for its recognition by human T cell clones. J. Exp. Med. 179, 279–290.

Wucherpfennig, K. W., Zhang, J., Witek, C., Matsui, M., Modabber, Y., Ota, K., and Hafler, D. A. (1994b). Clonal expansion and persistence of human T cells specific for an immunodominant myelin basic protein peptide. J. Immunol. 150, 5581–5592.

Zamvil, S. S., and Steinman, L. (1990). The T lymphocyte in experimental allergic encephalomyelitis. Annu. Rev. Immunol. 8, 579–621.

Zhang, J., Markovic, S., Lacet, B., Raus, J., Weiner, H. L., and Hafler, D. A. (1994). Increased frequency of interleukin 2–responsive T cells specific for myelin basic protein and proteolipid protein in peripheral blood and cerebrospinal fluid of patients with multiple sclerosis. J. Exp. Med. 179, 973–984.